Human Breast Cell MDA-MB-436 based Proliferation Assay Service
Creative Biolabs' service delivers more than just an IC50 value; it provides a foundational understanding of your compound's activity against a highly aggressive tumor model. We offer the solution to the primary challenge in early oncology screening: establishing reliable, quantitative proof-of-concept data for novel agents. We deliver clear evidence of anti-proliferative potency—the concentration required to inhibit cell growth—enabling the rapid and confident prioritization of your therapeutic pipeline and saving valuable time and resources in the drug development process. Oncological research relies on these precise measurements.
Background Applications Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The MDA-MB-436 Model and Mechanistic Relevance
The MDA-MB-436 cell line, a cornerstone of preclinical oncology, models the aggressive triple-negative breast cancer (TNBC) subtype, characterized by a lack of ER, PR, and HER2 expression. Its intrinsic BRCA1 mutation and high proliferation rate make it an ideal, stringent model for identifying novel therapeutic agents. Our Human Breast Cell MDA-MB-436 based Proliferation Assay Service helps you accelerate lead compound validation and characterize the mechanism of action through precise IC50 determination and highly relevant cell cycle and viability analysis in a high-throughput format. We provide the reliable, quantitative data needed to confidently advance therapies targeting the most resilient tumor cells.
Discover How We Can Help - Request a Consultation
Applications of Our Assay
Workflow: Precision Screening and Mechanistic Insight
Creative Biolabs employs a systematic, quality-controlled workflow to ensure every data point is accurate and actionable, setting the stage for subsequent mechanistic studies.
Publication
This study reveals the anti-tumor activity of SL4, a chalcone based compound, against aggressive breast cancer cell lines. SL4 strongly inhibits proliferation in vitro and in vivo with low IC50 values. Mechanistically, SL4 induces G2/M cell cycle arrest by activating the MAPK (JNK and ERK) pathways, which upregulate p21 and suppress the cdc2/cyclin B1 complex. Demonstrating a good safety profile, SL4 is a promising multi-target anticancer candidate for aggressive breast cancers.
Fig.1 SL4 inhibits the growth and colony formation of breast cancer cells. 1
Why Choose Us
Creative Biolabs is uniquely positioned as your partner against TNBC, combining a robust technical platform with deep expertise in aggressive tumor models. We offer scientific guidance rooted in the latest research, moving beyond simple assay execution. Our key features include proprietary cell culture methods that minimize cellular drift and quality control standards that exceed industry benchmarks. We provide high-throughput capability for the rapid, simultaneous screening of large compound libraries, accelerating your drug discovery pipeline against challenging TNBC phenotypes.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q1: Is the MDA-MB-436 assay more challenging or relevant than using a less aggressive line like MCF-7?
A1: The MDA-MB-436 line is a more stringent and clinically relevant model for TNBC. While MCF-7 is useful, MDA-MB-436's aggressive, BRCA1-mutant phenotype ensures that a compound identified here is truly potent against the most difficult subtype.
Q2: Can I use this service to screen large biologics?
A2: Absolutely. Our platform is flexible and optimized for both small-molecule compounds and large biologics. We can adjust the concentration ranges, incubation times, and assay media to suit the specific characteristics of your therapeutic agent.
Q3: Can the simple proliferation assay data help me understand if my compound is killing the cells (cytotoxic) or just stopping their growth (cytostatic)?
A3: Yes, a simple proliferation assay provides initial clues. By analyzing the shape of the dose-response curve and comparing short and long incubation times, we can guide you towards a cytotoxic (cell-killing) or cytostatic (growth-arresting, like G2/M) mechanism.
Customer Review
-
High-Accuracy IC50
Using Creative Biolabs' service in our research has significantly improved the validation speed of our novel USP1 inhibitor, providing the most accurate IC50 data we've seen on this aggressive line. - Mar*** W
-
Superior Quality Control
Creative Biolabs' IC50 results showed superior assay window and quality control compared to another vendor, enabling the confident distinction of a potent 1.2 μM lead compound from a background compound of 5 μM. - Kirs*** S
Related Services
To fully characterize your anti-TNBC drug candidate, we recommend complementing the proliferation assay with these critical follow-up services:
Oxidative Stress Analysis Service
Creative Biolabs offers oxidative stress-induced cardiotoxicity analysis services. We use sensitive methods to evaluate the effects of anticancer agents on heart health, assessing oxidative stress levels, apoptosis, and myocardial cell damage.
Learn More →
Overcoming Cancer Resistance Solutions
Creative Biolabs offers comprehensive services to combat cancer resistance. We leverage novel drug delivery platforms and genomics to identify and overcome resistance mechanisms.
Learn More →
Contact Us
The MDA-MB-436 based proliferation assay service provides the high-quality, actionable data you need to validate your lead compounds against the most challenging form of breast cancer. Our commitment to precision, speed, and scientific rigor ensures your oncology project moves forward with confidence.
Ready to initiate your screening project or need a custom assay design? Our team of cell domain experts is standing by to assist you.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Wang, Li-Hui, et al. "Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK-dependent p21 signaling pathway." Scientific Reports 6.1 (2016). Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/srep36486
